Dr. James Tananbaum is the founding chief executive officer of the company called Foresite Capital. He has been leading successful investments in more than a dozen successful companies working in the field of health care. Some of the companies include Jazz Pharmaceuticals, Amerigroup, and Amira Pharmaceuticals which was acquired by the renowned Bristol-Myers Squibb.
Dr. James Tananbaum is the founder of the company GelTex Pharmaceuticals and was responsible for the management of the company. GelTex Pharmaceuticals was later sold off to the larger corporation of Genzyme for the price of almost two billion dollars. Dr. James Tananbaum is also the founder of the company called Theravance. More details can be found on Crunchbase.
Dr. James Tananbaum acquired his education from a few of the most renowned academic institutions in the world – the Harvard University and the Yale University. Dr. James Tananbaumearned hs bachelor’s degree and his B. S. E . E. from the Yale University. After that, he became a student at the Harvard University – Medical School and graduated with an M. D. Next, Dr. James Tananbaum pursued an M. B. A from the Harvard University – School of Business.
The large corporation of Foresite Capital Management has been in the business since the year of 2010. Foresite capital management is dedicated to the investing in the growth of health care businesses. The company does investments in businesses that work in all and any aspects of the industry of health care such as genomics and biotechnology, Diagnostics and services as well as other medical devices. The investment company of Foresite Capital Management has office buildings in a few places in the united states – The Philadelphia area, New York City, as well as in the San Francisco Bay Area.
Other successes of Dr. James Tananbaum include Theravance (1997 – 2000), Sierra Ventures ( 1993 – 1997), GelTex Pharmaceuticals ( 1993 – 19997), among others.
Dr. James Tananbaum has done philanthropy as well as volunteer work at the Yale University as well as at the Harvard-MIT HST Program. He was at the position of President for the Advisory Board of the Yale University as well as an Advisor for the Harvard – MIT HST Program. His career has been extremely successful.